Superworth

Exozymes EPS EXOZ

Diluted earnings per share by quarter and over the last twelve months, from 2023.

Last 12 months, to Jun 30, 2026
−$1.20
Latest quarter, Q2 FY26
−$0.33
Fiscal year 2025
−$1.09

Exozymes' earnings per share was −$1.20 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.33.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.09n/a
FY2024−$0.90n/a
FY2023n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.33n/a−$1.20
Q1 FY26−$0.28n/a−$1.15
Q4 FY25−$0.32n/a−$1.09
Q3 FY25−$0.27n/a−$1.02
Q2 FY25−$0.28n/a−$1.02
Q1 FY25−$0.22n/a−$0.96
Q4 FY24−$0.25n/a−$0.90
Q3 FY24−$0.27n/a−$0.83
Q2 FY24−$0.22n/a−$0.64
Q1 FY24−$0.16n/an/a
Q4 FY23−$0.18n/an/a
Q3 FY23−$0.08n/an/a

Against its peers

Companies in Healthcare nearest Exozymes' size, closest first, today.

CompanyEPS, 12 monthsGrowth
EXOZExozymes−$1.20
NEPHNephros$0.16+33% a year
ATNMActinium Pharmaceuticals$0.36
APTAlpha Pro Tech$0.41+24% a year
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
ICCCImmucell$0.08−58% a year
KEQUKewaunee Scientific$2.76−33% a year
PDEXPro DEX$4.11+52% a year
PLXProtalix BioTherapeutics$0.23+283% a year
NATRNatures Sunshine Products$1.01+36% a year
Peer median$0.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Exozymes

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.